BMRN

BMRN

USD

BioMarin Pharmaceutical Inc. Common Stock

$52.520-0.040 (-0.076%)

即時價格

Healthcare
生物科技
美國

價格圖表

Loading Chart...

關鍵指標

市場指標
公司基本面
交易統計

市場指標

開盤

$52.560

最高

$52.760

最低

$51.800

交易量

2.96M

公司基本面

市值

10.1B

行業

生物科技

國家

United States

交易統計

平均交易量

2.34M

交易所

NMS

貨幣

USD

52週範圍

最低 $51當前 $52.520最高 $73.51

相關新聞

Analyst Upgrades

Bernstein Maintains Outperform on BioMarin Pharmaceutical, Lowers Price Target to $88

Bernstein analyst William Pickering maintains BioMarin Pharmaceutical with a Outperform and lowers the price target from $95 to $88.

查看更多
Bernstein Maintains Outperform on BioMarin Pharmaceutical, Lowers Price Target to $88
Analyst Upgrades

Truist Securities Maintains Buy on BioMarin Pharmaceutical, Lowers Price Target to $80

Truist Securities analyst Joon Lee maintains BioMarin Pharmaceutical with a Buy and lowers the price target from $90 to $80.

查看更多
Truist Securities Maintains Buy on BioMarin Pharmaceutical, Lowers Price Target to $80
Analyst Upgrades

Wells Fargo Maintains Overweight on BioMarin Pharmaceutical, Lowers Price Target to $70

Wells Fargo analyst Mohit Bansal maintains BioMarin Pharmaceutical with a Overweight and lowers the price target from $90 to $70.

查看更多
Wells Fargo Maintains Overweight on BioMarin Pharmaceutical, Lowers Price Target to $70
Analyst Upgrades

Barclays Maintains Overweight on BioMarin Pharmaceutical, Lowers Price Target to $80

Barclays analyst Gena Wang maintains BioMarin Pharmaceutical with a Overweight and lowers the price target from $86 to $80.

查看更多
Barclays Maintains Overweight on BioMarin Pharmaceutical, Lowers Price Target to $80
Analyst Upgrades

HC Wainwright & Co. Maintains Neutral on BioMarin Pharmaceutical, Lowers Price Target to $55

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains BioMarin Pharmaceutical with a Neutral and lowers the price target from $60 to $55.

查看更多
HC Wainwright & Co. Maintains Neutral on BioMarin Pharmaceutical, Lowers Price Target to $55
Analyst Upgrades

Morgan Stanley Maintains Overweight on BioMarin Pharmaceutical, Lowers Price Target to $98

Morgan Stanley analyst Matthew Harrison maintains BioMarin Pharmaceutical with a Overweight and lowers the price target from $104 to $98.

PR Newswire

BioMarin Reports Third Quarter 2025 Results and Provides Corporate Update

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced financial results for the third quarter ended September 30, 2025. "We are pleased with...